← Back to Search

Other

EP262 for Eczema (EASE Trial)

Phase 2

Recruiting

Research Sponsored by Escient Pharmaceuticals, Inc

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Clinically confirmed diagnosis of active atopic dermatitis for at least 1 year

BSA of 3% to 20% and a vIGA-AD score of ≥3

Timeline

Screening 3 weeks

Treatment Varies

Follow Up measured from day 1 to end of study or early termination (up to 10 weeks)

Awards & highlights

EASE Trial Summary

This trial will study if a new drug can help people with a skin condition called atopic dermatitis.

Who is the study for?

This trial is for people with atopic dermatitis (eczema) covering 3-20% of their body and a moderate to severe score on a skin assessment. They must have had eczema for at least one year but can't join if they need antibiotics for an infection or have other itchy skin diseases.Check my eligibility

What is being tested?

The study tests EP262, an oral medication, against a placebo (a pill without active medicine). Participants won't know which one they're taking. The goal is to see how safe EP262 is and how it affects the body in those with eczema.See study design

What are the potential side effects?

Possible side effects are not detailed here, but generally could include reactions related to the immune system since EP262 targets atopic dermatitis, which involves immune dysregulation.

EASE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with active atopic dermatitis for over a year.

Select...

My skin condition affects 3% to 20% of my body and is moderately severe.

EASE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ measured from day 1 to end of study or early termination (up to 10 weeks)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~measured from day 1 to end of study or early termination (up to 10 weeks)

This trial's timeline: 3 weeks for screening, Varies for treatment, and measured from day 1 to end of study or early termination (up to 10 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Safety and tolerability of EP262

Secondary outcome measures

Effect of EP262 on skin gene expression

Effect of EP262 on skin histology

EASE Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: EP262 150 mgExperimental Treatment1 Intervention

Group II: PlaceboPlacebo Group1 Intervention

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Escient Pharmaceuticals, IncLead Sponsor

4 Previous Clinical Trials

267 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the current trial permit minors to participate?

"The requirements for inclusion in this experiment are that patients must be over 18 and under 80 years of age."

Answered by AI

Has this clinical trial opened its doors to more participants?

"This medical study is actively recruiting participants, as per the information on clinicaltrials.gov. It was first published on November 1st 2023 and has been recently updated on the 16th of that same month."

Answered by AI

What is the upper limit for participants in this medical experiment?

"Indeed, the information on clinicaltrials.gov shows that this trial is currently soliciting volunteers. This research was first announced on November 1st 2023 and has been updated as recently as November 16th 2023. The study requires 30 participants from a single medical centre."

Answered by AI

Is there a specific demographic of people that would be suitable for enrollment in this medical experiment?

"This clinical trial is accepting applications from those aged between 18 and 80 with atopic dermatitis. Approximatively 30 patients are needed in total."

Answered by AI